PREGNANCY AND LACTATION IN PATIENTS WITH PSORIASIS

Florica Șandru; Adelina Popa; Adina Nenciu; C. G. Nenciu; R. Petca; M. C. Dumitrașcu

doi:10.33695/rjcr.v3i1.47

Florica Șandru “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania & “Elias” Emergency University Hospital, Bucharest, Romania
Adelina Popa “Elias” Emergency University Hospital, Bucharest, Romania
Adina Nenciu Bucharest Emergency University Hospital, Bucharest Romania
C. G. Nenciu “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
R. Petca ”Professor Dr. Theodor Burghele” Clinical Hospital, Bucharest, Romania
M. C. Dumitrașcu Bucharest Emergency University Hospital, Bucharest Romania & “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

DOI: https://doi.org/10.33695/rjcr.v3i1.47

Keywords: pregnancy, psoriasis, drug safety management, pregnancy outcome

Abstract

Psoriasis is an inflammatory chronic, common skin disease that represents a great burden affecting people of all ages. It has no clear cause and although there are treatments none of them can guaranty remission. This pathology has a significant negative impact on people in all countries, affecting between 0.09% and 11.43%, which means at least 100 million people worldwide. A particular category is represented by pregnant women. Although it is reported that 55% of the patients have improved symptomatology during pregnancy, 21% reported no change and 23% suffered worsening of the illness. Psoriasis can be difficult to manage due to fluctuations in hormone levels. Even if patients can experience improvements during pregnancy, most of the women report worsening in the post-partum period (4-6 weeks). Pregnancy and lactation can also interfere with specific treatment for psoriasis. Psoriasis can increase the risk of gestational, diabetes, pre-eclampsia and hypertension in pregnancy, increased risk of preterm birth, low birth weight and emergency caesarean section. In order to have a positive outcome for the mother and the baby, careful multidisciplinary management is needed. The aim of this review is to summarize the notions in the literature regarding pregnancy with psoriasis and the current treatment trend in this group of patients.

References

[1] WHO Library Cataloguing-in-Publication Data. Global report on psoriasis. ISBN 978 92 4 156518 9 (NLM classification: WR 205) 2016.
[2] W-H Boehncke, MP Schön. Psoriasis. Lancet. 2015;386(9997):983–94.
[3] AE Tauscher, AB Fleischer, KC Phelps, SR Feldman. Psoriasis and pregnancy. J Cutan Med Surg 2002; 6:561–70.
[4] EJ Horn, CD Chambers, A Menter, AB Kimball. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol. 2009;61: e5-8.
[5] Liljana Mervic. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol APA. 2014; 23:27-31. doi: 10.15570/actaapa.2014.7.
[6] C De Simone, G Caldarola, G Moretta, L Piscitelli, F Ricceri, F Prignano. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol. 2019 Jun;154(3):305-314. doi: 10.23736/S0392-0488.18.06255-7.
[7] S Weatherhead, SC Robson, NJ Reynolds. Management of psoriasis in pregnancy [published correction appears in BMJ. 2007 Sep 1;335(7617):0]. BMJ. 2007; 334(7605): 1218–1220. doi:10.1136/bmj.39202.518484.80.
[8] SP Raychaudhuri, T Navare, J Gross, SK Raychaudhuri. Clinical course of psoriasis during pregnancy. Int J Dermatol. 2003;42(7):518–520.
[9] JE Murase, KK Chan, TJ Garite, DM Cooper, GD Weinstein. Hormonal effect on psoriasis in pregnancy and postpartum. Arch Dermatol. 2005;141(1):601–606.
[10] AS Boyd, LF Morris, CM Phillips, MA Menter. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol. 1996 Mar; 35(3):169-72.
[11] L Martina Porter, J Stephen Lockwood, B Alexa Kimball. Update on biologic safety for patients with psoriasis during pregnancy. International Journal ofWomen's Dermatology 3 (2017) 21–25.
[12] JE Gudjonsson, A Karason, EH Runarsdottir, AA Antonsdottir, VB Hauksson, HH Jónsson, J Gulcher, K Stefansson, H Valdimarsson. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients--an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol. 2006 Apr; 126(4):740-5.
[13] GA Vena, N Cassano, G Bellia, D Colombo. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl). 2015; 5:83–95. Published 2015 May 18. doi:10.2147/PTT.S82975.
[14] E Cohen-Barak, Z Nachum, D Rozenman, M Ziv. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2011 Sep; 25(9):1041-7.
[15] HC Lin, SF Chen, HC Lin, YH Chen. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Ann Rheum Dis. 2010 Apr; 69(4):715-7.
[16] YW Yang, CS Chen, YH Chen, HC Lin. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol. 2011;64(1):71–77.
[17] G Ben-David, E Sheiner, M Hallak, A Levy. Pregnancy outcome in women with psoriasis. J Reprod Med. 2008 Mar; 53(3):183-7.
[18] XT Lima, V Janakiraman, MD Hughes, AB Kimball. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol. 2012 Jan; 132(1):85-91.
[19] EJ Horn, CD Chambers, A Menter, AB Kimball, International Psoriasis Council. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol. 2009 Aug; 61(2): e5-8.
[20] L Mervic. Management of moderate to severe plaque psoriasis in pregnancy and lactation in the era of biologics. Acta Dermatovenerol Alp Pannonica Adriat. 2014; 23(2):27-31.
[21] L Park-Wyllie, P Mazzotta, A Pastuszak, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
[22] JE Murase, MM Heller, DC Butler. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014 Mar; 70(3): 401.e1-14; quiz 415.
[23] I Wakefield, S Stephens, R Foulkes, A Nesbitt, T Bourne. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNF alpha PEGylated Fab' monoclonal antibody. Toxicol Sci 2011; 122:170–6.
[24] F Förger, PM Villiger. Treatment of rheumatoid arthritis during pregnancy: Present and future. Expert Rev Clin Immunol 2016; 12:937–44.
[25] M Julsgaard, LA Christensen, PR Gibson, RB Gearry, J Fallingborg, CL Hvas, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016; 151:110–9.
[26] CD Chambers, DL Johnson. Emerging data on the use of anti-tumor necrosis factoralpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol 2012; 94:607–11.
[27] JP Gisbert, M Chaparro. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108:1426–38.